Literature DB >> 2852412

Interaction of Epstein-Barr virus DNA polymerase with aphidicolin, phosphonoformate and 5'-GMP.

J S Li1, Y C Cheng.   

Abstract

Epstein-Barr virus (EBV)-specified DNA polymerase was purified from P3HR-1 cells, a Burkitt lymphoma EBV producer cell line, treated with phorbol-12,13-dibutyrate (PDB) and n-butyrate. Its inhibition by aphidicolin, phosphonoformate (PFA) and 5'-GMP was examined. Aphidicolin could inhibit EBV DNA polymerase competitively with respect to dATP and dCTP and noncompetitively with respect to dGTP and dTTP; whereas 5'-GMP was a noncompetitive inhibitor with respect to all four dNTPs. Combinations of aphidicolin and PFA, or PFA and 5'-GMP, produced a mutually exclusive inhibition pattern of EBV DNA polymerase that suggested that the binding sites of these compounds on the enzyme molecule are kinetically overlapping.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852412     DOI: 10.1007/bf00257099

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  20 in total

1.  Effect of aphidicolin on viral and human DNA polymerases.

Authors:  G Pedrali-Noy; S Spadari
Journal:  Biochem Biophys Res Commun       Date:  1979-06-27       Impact factor: 3.575

2.  Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate.

Authors:  J M Reno; L F Lee; J A Boezi
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

3.  Inhibition of herpes simplex virus-induced DNA polymerase, cellular DNA polymerase alpha, and virus production by aphidicolin.

Authors:  R A Dicioccio; K Chadha; B I Sahai Srivastava
Journal:  Biochim Biophys Acta       Date:  1980-09-19

4.  Identification and characterization of a DNase induced by Epstein-Barr virus.

Authors:  R S Tan; A K Datta; Y C Cheng
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

5.  Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha.

Authors:  S Ikegami; T Taguchi; M Ohashi; M Oguro; H Nagano; Y Mano
Journal:  Nature       Date:  1978-10-05       Impact factor: 49.962

6.  The mode of action of aphidicolin on DNA synthesis in isolated nuclei.

Authors:  M Oguro; M Shioda; H Nagano; Y Mano; F Hanaoka; M Yamada
Journal:  Biochem Biophys Res Commun       Date:  1980-01-15       Impact factor: 3.575

7.  Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma.

Authors:  R S Tan; J S Li; S P Grill; L M Nutter; Y C Cheng
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

8.  Novel interaction of aphidicolin with herpes simplex virus DNA polymerase and polymerase-associated exonuclease.

Authors:  K B Frank; D D Derse; K F Bastow; Y C Cheng
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

9.  Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

Authors:  B Eriksson; A Larsson; E Helgstrand; N G Johansson; B Oberg
Journal:  Biochim Biophys Acta       Date:  1980-03-28

10.  Demonstration of a stimulatory protein for virus-specified DNA polymerase in phorbol ester-treated Epstein-Barr virus-carrying cells.

Authors:  J F Chiou; J K Li; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more
  3 in total

1.  Identification and some properties of a unique DNA polymerase from cells infected with human B-lymphotropic virus.

Authors:  A R Bapat; A J Bodner; R C Ting; Y C Cheng
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Primer terminus recognition and highly processive replication by Epstein-Barr virus DNA polymerase.

Authors:  T Tsurumi
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

3.  Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report.

Authors:  Yasuaki Mushiga; Tatsunori Komoto; Norihiro Nagai; Yoko Ozawa
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.